SCHEMBL9925948

SCHEMBL9925948

CCc1cnc(-n2ccnc2C)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.43
CYP2E1 P05181 1/20 0.43
CYP2A6 P11509 1/20 0.43
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP19A1 P11511 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
ALDH1A1 P00352 2/20 0.38
POLB P06746 1/20 0.38
KMT2A Q03164 1/20 0.38
KDR P35968 1/20 0.37
TUBB4A P04350 2/20 0.36
TUBB P07437 2/20 0.36
TUBA3C P0DPH7 2/20 0.36
TUBA1B P68363 2/20 0.36
TUBA4A P68366 2/20 0.36
TUBB4B P68371 2/20 0.36
TUBB3 Q13509 2/20 0.36
TUBB2A Q13885 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9925917 0.81 CYP3A4 (0.46) CYP3A4CYP2E1CYP2A6CYP1A2CYP2D6
SCHEMBL20486007 0.78 CYP3A4 (0.43) CYP3A4CYP2E1CYP2A6CYP1A2CYP2D6
SCHEMBL15692426 0.78 CYP3A4 (0.43) CYP3A4CYP2E1CYP2A6CYP1A2CYP2D6
SCHEMBL18708709 0.78 CYP3A4 (0.43) CYP3A4CYP2E1CYP2A6CYP1A2CYP2D6
SCHEMBL18672393 0.77 CYP3A4 (0.37) CYP3A4CYP2E1CYP2A6CYP1A2CYP2D6
SCHEMBL9924603 0.75 CYP3A4 (0.41) CYP3A4CYP2E1CYP2A6CYP1A2CYP2D6
SCHEMBL179311 0.75 CYP3A4 (0.45) CYP3A4CYP2E1CYP2A6CYP1A2CYP2D6
SCHEMBL18879246 0.75 CYP3A4 (0.38) CYP3A4CYP2E1CYP2A6CYP1A2CYP2D6
SCHEMBL11350936 0.74 CYP3A4 (0.40) CYP3A4CYP2E1CYP2A6CYP1A2CYP2D6
SCHEMBL2559369 0.74 CYP3A4 (0.40) CYP3A4CYP2E1CYP2A6CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9822131-B2 Certain chemical entities, compositions and methods INTELLIKINE LLC (US) 2017-11-21 US disclosed
US-20170281614-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS INTELLIKINE LLC 2017-10-05 US disclosed
EP-2571357-B1 CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION INFINITY PHARMACEUTICALS INC (US) 2016-07-06 EP disclosed
US-20120149701-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS INTELLIKINE, INC. 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149701-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS PIK3CA, AKT3, PIK3C2A CYP3A4 1925/4885CYP2E1 2738/4885CYP2A6 2926/4885
US-20170281614-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS PIK3CA, PIK3CG, PIK3CB CYP3A4 1611/4885CYP2E1 2138/4885CYP2A6 2476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.